Solanezumab did not slow cognitive decline in the A4 preclinical Alzheimer's disease trial, weakening soluble amyloid-beta targeting as prevention monotherapy.

Evidence span

Solanezumab did not slow cognitive decline in the A4 preclinical Alzheimer's disease trial, weakening soluble amyloid-beta targeting as prevention monotherapy.

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Preclinical Alzheimer's disease with elevated amyloid; solanezumab prevention trial.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required